Tags

Type your tag names separated by a space and hit enter

Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?
Clin J Am Soc Nephrol. 2006 Sep; 1(5):933-9.CJ

Abstract

Re-analysis of the North American IgA Nephropathy Study suggested that efficacy of omega-3 polyunsaturated fatty acids (omega-3 PUFA) was dosage-dependent on the basis of body size and plasma omega-3/omega-6 and eicosapentaenoic acid (EPA)/arachidonic acid (AA) ratios. The objective of this study was to confirm these assertions. Data from a previously reported randomized 2-yr clinical trial in which two dosages of an ethyl ester omega-3 PUFA (Omacor) were given to 73 high-risk patients with IgA nephropathy were reviewed. Omacor also was used in the North American IgA Nephropathy Study. Parameters included body weight; body mass index (BMI); plasma phospholipid AA, EPA, and docosahexanoic acid (DHA) levels and serum creatinine and 24-h urine protein (UP) levels during the 2-yr trial; and time to ESRD after 6.4 yr. Plasma phospholipid levels of EPA, DHA, and EPA/AA ratios were significantly inversely correlated with increasing body weight and BMI in the Omacor 4-g dosage group but not in the Omacor 8-g dosage group. Conversely, increasing levels of lipid parameters were observed with increasing dosages of Omacor (EPA+DHA) in grams per kilogram of body weight at 6 wk of treatment. None of the plasma omega-3 PUFA levels, EPA/AA ratios, or Omacor dosage per kilogram was significantly associated with reciprocal serum creatinine or UP slopes during the 2-yr trial or with ESRD. This post hoc analysis of body weight and BMI, plasma omega-3 PUFA status, and renal outcome did not find that treatment efficacy of omega-3 PUFA was dosage dependent on the basis of body size.

Authors+Show Affiliations

Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA. donadio.james@mayo.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17699310

Citation

Donadio, James V., et al. "Is Body Size a Biomarker for Optimizing Dosing of Omega-3 Polyunsaturated Fatty Acids in the Treatment of Patients With IgA Nephropathy?" Clinical Journal of the American Society of Nephrology : CJASN, vol. 1, no. 5, 2006, pp. 933-9.
Donadio JV, Bergstralh EJ, Bibus DM, et al. Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy? Clin J Am Soc Nephrol. 2006;1(5):933-9.
Donadio, J. V., Bergstralh, E. J., Bibus, D. M., & Grande, J. P. (2006). Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy? Clinical Journal of the American Society of Nephrology : CJASN, 1(5), 933-9.
Donadio JV, et al. Is Body Size a Biomarker for Optimizing Dosing of Omega-3 Polyunsaturated Fatty Acids in the Treatment of Patients With IgA Nephropathy. Clin J Am Soc Nephrol. 2006;1(5):933-9. PubMed PMID: 17699310.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy? AU - Donadio,James V, AU - Bergstralh,Eric J, AU - Bibus,Douglas M, AU - Grande,Joseph P, Y1 - 2006/08/02/ PY - 2007/8/19/pubmed PY - 2007/8/31/medline PY - 2007/8/19/entrez SP - 933 EP - 9 JF - Clinical journal of the American Society of Nephrology : CJASN JO - Clin J Am Soc Nephrol VL - 1 IS - 5 N2 - Re-analysis of the North American IgA Nephropathy Study suggested that efficacy of omega-3 polyunsaturated fatty acids (omega-3 PUFA) was dosage-dependent on the basis of body size and plasma omega-3/omega-6 and eicosapentaenoic acid (EPA)/arachidonic acid (AA) ratios. The objective of this study was to confirm these assertions. Data from a previously reported randomized 2-yr clinical trial in which two dosages of an ethyl ester omega-3 PUFA (Omacor) were given to 73 high-risk patients with IgA nephropathy were reviewed. Omacor also was used in the North American IgA Nephropathy Study. Parameters included body weight; body mass index (BMI); plasma phospholipid AA, EPA, and docosahexanoic acid (DHA) levels and serum creatinine and 24-h urine protein (UP) levels during the 2-yr trial; and time to ESRD after 6.4 yr. Plasma phospholipid levels of EPA, DHA, and EPA/AA ratios were significantly inversely correlated with increasing body weight and BMI in the Omacor 4-g dosage group but not in the Omacor 8-g dosage group. Conversely, increasing levels of lipid parameters were observed with increasing dosages of Omacor (EPA+DHA) in grams per kilogram of body weight at 6 wk of treatment. None of the plasma omega-3 PUFA levels, EPA/AA ratios, or Omacor dosage per kilogram was significantly associated with reciprocal serum creatinine or UP slopes during the 2-yr trial or with ESRD. This post hoc analysis of body weight and BMI, plasma omega-3 PUFA status, and renal outcome did not find that treatment efficacy of omega-3 PUFA was dosage dependent on the basis of body size. SN - 1555-905X UR - https://www.unboundmedicine.com/medline/citation/17699310/Is_body_size_a_biomarker_for_optimizing_dosing_of_omega_3_polyunsaturated_fatty_acids_in_the_treatment_of_patients_with_IgA_nephropathy L2 - http://cjasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=17699310 DB - PRIME DP - Unbound Medicine ER -